Apimeds Pharmaceuticals US, Inc. (APUS) shareholders
Close on Nov 13, 2026Market cap $3.37MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Apimeds Inc. Joint filing with Inscobee Inc. (16.70%) | 4,316,618 | 34.30% | 13D (active) amendment | May 7, 2026 |
| Waqas Khatri Joint filing with Ayrton Capital LLC (9.99%), Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (9.99%) | 1,397,021 | 9.99% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of APUS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hemenway Trust Co LLC | 27,400 | 1.82% | $246.60K | – | 0.02% |
| Vanguard Capital Management LLC | 6,365 | 0.42% | $57.29K | −3,228 | 0.00% |
| Geode Capital Management, LLC | 3,512 | 0.23% | $31.60K | −493 | 0.00% |
| Vanguard Fiduciary Trust Co | 2,404 | 0.16% | $21.64K | – | 0.00% |
| Jane Street Group, LLC | 1,600 | 0.11% | $14.39K | New | 0.00% |
| UBS Group AG | 1,182 | 0.08% | $10.64K | +763 | 0.00% |
| Tower Research Capital LLC (TRC) | 166 | 0.01% | $1.50K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 7 | 0M | 2.8% | 2 / 1 | 2 / 1 | 0M | 0M |
| Q1 2026 | 6 | 0M | 3.0% | 3 / 2 | 0 / 3 | 0M | 0M |
| Q4 2025 | 7 | 0M | 2.6% | 3 / 3 | 0 / 4 | 0M | 0M |
| Q3 2025 | 8 | 0M | 2.7% | 6 / 1 | 0 / 4 | 0M | 0M |
| Q2 2025 | 6 | 0M | 1.8% | 6 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Erik C. Emerson | Chief Executive Officer, Director | 750,000 | 49.70% | Oct 17, 2025 |
| Christopher Kim | Chairman and CMO, Director | 277,500 | 18.39% | Oct 17, 2025 |
| Sungjoon Chae | Co-Chief Executive Officer | – | – | Nov 5, 2026 |
| Eric Michael Sherb | Chief Financial Officer | – | – | Nov 2, 2026 |
| Vin Menon | Co-Chief Executive Officer | – | – | Nov 2, 2026 |
| Mark Corrao | Chief Financial Officer | – | – | May 8, 2025 |
| Bennett Weintraub | Director | – | – | Nov 13, 2025 |
| Jakap Koo | Director | 643,885 | 42.67% | Nov 13, 2025 |
| Hankil Yoon | Director | – | – | Nov 13, 2025 |
| Elona Kogan | Director | – | – | Nov 13, 2025 |
| Carol A. O'Donnell | Director | – | – | Nov 13, 2025 |
| Inc. Inscobee | 10% owner | 5,801,234 | 384.41% | Nov 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christopher Kim Chairman and CMO, Director | May 16, 2025 | Award | +250,000 | – | – | 277,500 |
| Erik C. Emerson Chief Executive Officer, Director | May 16, 2025 | Award | +750,000 | – | – | 750,000 |
| Christopher Kim Chairman and CMO, Director | May 14, 2025 | Buy | +7,730 | $1.86 | $14.38K | 27,500 |
| Christopher Kim Chairman and CMO, Director | May 13, 2025 | Buy | +19,770 | $1.82 | $35.98K | 19,770 |
| Inc. Inscobee 10% owner | May 12, 2025 | Conversion | +71,090 | $2.60 | $184.83K | 2,055,706 |
| Inc. Inscobee 10% owner | May 12, 2025 | Conversion | +44,041 | $2.60 | $114.51K | 2,099,747 |
| Jakap Koo Director | May 12, 2025 | Buy | +28,500 | $1.99 | $56.72K | 643,885 |
| Inc. Inscobee 10% owner | May 12, 2025 | Buy | +500,000 | $4.00 | $2.00M | 1,984,616 |
| Inc. Inscobee 10% owner | May 12, 2025 | Conversion | +182,002 | $2.60 | $473.21K | 4,316,618 |
| Inc. Inscobee 10% owner | May 12, 2025 | Conversion | +71,090 | $2.60 | $184.83K | 4,387,708 |
| Inc. Inscobee 10% owner | May 12, 2025 | Conversion | +44,041 | $2.60 | $114.51K | 2,028,657 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Apimeds Pharmaceuticals US's stock actually held short. Settlement fails (shares not delivered on time) peaked at 583,360 shares on Sep 25, 2026 over the last 90 days.
See a number that looks wrong?